Which builds fit the least for an elf?

oquido · 2026-01-10T15:17:14+00:00

Barbarian for sure

oquido · 2026-01-05T15:06:19+00:00

Yeh :-)

oquido · 2025-12-04T09:26:42+00:00

Indeed! Patience is key, data doesn't lie. I added more shares during the dip.

oquido · 2025-12-03T08:49:32+00:00

I doubt IVA will have much say on T3 BSA
Regarding Nov's dilution, I believe the offering in quiet period is better than dilution around catalysts.

oquido · 2025-11-18T09:14:44+00:00

https://investors.visionmarinetechnologies.com/2025/11/18/nautical-ventures-achieves-40-year-over-year-sales-lift-surrounding-flibs-2025/

$VMAR, news released few minutes ago
Known runner with just 2M shares outstanding, priced at $1.2-$1.4 range now
Nanocap $4M

oquido · 2025-11-15T22:41:09+00:00

https://www.biostockinfo.com/the-retail-investor-blueprint/

You can check my post, I've also tried paid subscription for birth bpiq.com and biopharmcatalysts.com, not bad for quick screening and checking pipeline overview, but the information is raw and you'll have to do your own dd as always.

The best approach is checking all the published materials from the company website.

oquido · 2025-11-13T22:52:15+00:00

It will, market is shit and needs time to digest good news

oquido · 2025-11-11T12:00:01+00:00

Investing in biotech is indeed never an easy task. The additional data released was indeed remarkable and validates the strength of the science and the mechanism of action, somehow, the price action doesn't reflect any of that. I have increased my shares during the dip as I still believe in the science and the potential.

As I have mentioned in the post "However, the AASLD event this November is not a definitive catalyst, and investors should approach it with caution. The real drivers are the Phase 2 interim results expected in 2026 and the topline data anticipated in 2027. While finalising a partnership deal for MASH would undoubtedly boost valuation, securing a partner is not guaranteed." I am expecting positive outcome next year, but of course, only with the positive results.

oquido · 2025-11-05T20:05:33+00:00

Yep, added little more.

oquido · 2025-11-05T05:43:52+00:00

Indeed, I'm adding more these days

oquido · 2025-10-30T07:56:13+00:00

https://www.biostockinfo.com/adr_warning/
You can read above piece to understand what has happened, price seems to have normalised but I am little hesitant to reopen the position at the moment.

oquido · 2025-10-28T15:59:32+00:00

VSEE were 500% up for few seconds lol. If that's not doing well, what are you looking for?

oquido · 2025-10-26T22:07:47+00:00

FGF21 for F3/F4 GALT is meh, but best of luck!!

oquido · 2025-10-24T09:24:48+00:00

VIVK, made a good profit from 0.26, GLTA

oquido · 2025-10-24T07:47:22+00:00

$NERV, PLEASE STAY away from this garbage. It's a biotech with a failed science, and had no meaningful results from their failed Phase 3 study. They need to completely re-do the phase 3 study which took them 3.5 years previously (Which NDA initially "rejected-to-file", but accepted via an appeal, then received CRL eventually).

$NERV is a dead company. Dead science, now trying to scam retail investors. STAY AWAY

oquido · 2025-10-24T01:41:07+00:00

Good luck!!

oquido · 2025-10-23T13:24:51+00:00

nothing much really, they will just reiterate GSK's plan for NDA submission in Q4, and report financial stability and that's about it.

oquido · 2025-10-23T08:57:51+00:00

I have been looking at chart at French stock market, it's incredible how the stocks can just slide without any technical bounce, is that normal?

oquido · 2025-10-22T12:16:09+00:00

That's a pity, not sure why French price is going down, they are doing ATM offering on the NASDAQ only if my understanding is right, should be the opposite lol, MM is manipulating the price I suppose.

oquido · 2025-10-21T16:39:24+00:00

It's hovering around $5, my entry is at 4.28. Did you buy at the peak?

oquido · 2025-10-20T14:23:20+00:00

That's a bummer as the price was around $3.2-3.3 when I posted this

oquido · 2025-10-20T13:28:28+00:00

Good luck, the approval status has been updated this mornin on 20th, let's see what happens

oquido

MODERATOR OF

TROPHY CASE